Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature
Top Cited Papers
Open Access
- 2 April 2011
- journal article
- review article
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 28 (5) , 493-503
- https://doi.org/10.1007/s10585-011-9384-x
Abstract
Treating metastatic osteosarcoma (OS) remains a challenge in oncology. Current treatment strategies target the primary tumour rather than metastases and have a limited efficacy in the treatment of metastatic disease. Metastatic cells have specific features that render them less sensitive to therapy and targeting these features might enhance the efficacy of current treatment. A detailed study of the biological characteristics and behaviour of metastatic OS cells may provide a rational basis for innovative treatment strategies. The aim of this review is to give an overview of the biological changes in metastatic OS cells and the preclinical and clinical efforts targeting the different steps in OS metastases and how these contribute to designing a metastasis directed treatment for OS.Keywords
This publication has 85 references indexed in Scilit:
- Extracellular matrix: A gatekeeper in the transition from dormancy to metastatic growthPublished by Elsevier ,2010
- Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcomaCancer, 2009
- Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungsInternational Journal of Cancer, 2009
- Osteosarcoma incidence and survival rates from 1973 to 2004Cancer, 2009
- Cadherins and cancer: how does cadherin dysfunction promote tumor progression?Oncogene, 2008
- Dominant Negative LRP5 Decreases Tumorigenicity and Metastasis of Osteosarcoma in an Animal ModelClinical Orthopaedics and Related Research, 2008
- Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastasesClinical & Experimental Metastasis, 2007
- Metastasis: recent discoveries and novel treatment strategiesPublished by Elsevier ,2007
- p53-Deficient Cells Rely on ATM- and ATR-Mediated Checkpoint Signaling through the p38MAPK/MK2 Pathway for Survival after DNA DamageCancer Cell, 2007
- The Hallmarks of CancerCell, 2000